Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.K2M, a spinal device company, has entered into an agreement with Promethean Surgical Devices for the worldwide exclusive rights for all spinal applications of an injectable polymer technology which may be used to address numerous spinal disorders.
Subscribe to our email newsletter
K2M said that its commitment to a new biomaterials R&D division signals its continued drive to being a market leader in the complex spine market. In furtherance of this goal, the unique injectable polymer obtained from Promethean Surgical Devices (PSD) will serve as a platform for the development of new implantable technologies, the company said.
According to the company, this material has demonstrated properties that could lead to the development of a new treatment modality and earlier intervention to address pathologies, such as spinal nucleus degeneration, or less invasive surgical approaches for predictable annular repair.
Eric Major, president and CEO of K2M, said: “Acquiring this injectable polymer technology signals the beginning of a new phase in the growth of K2M and our commitment to the development of market leading technologies. Our financial strength at K2M is allowing us to invest in new R&D activities and we are very pleased to be partnering with PSD for the research and commercialization of this revolutionary material.”